Deligiannis Dimitrios, Anastasiou Ioannis, Mitropoulos Dionysios, Mitsos Panagiotis, Theocharis Stamatios
Department of Urology, Naval Hospital of Athens, Athens, GRC.
First Department of Urology, Medical School, Laiko Hospital, National and Kapodistrian University of Athens, Athens, GRC.
Cureus. 2024 Feb 28;16(2):e55121. doi: 10.7759/cureus.55121. eCollection 2024 Feb.
Background and objective The purpose of our study was to assess the expression of cannabinoid type 1 receptor (CB1R) and cannabinoid type 2 receptor (CB2R), including positivity, intensity, percentage, site of distribution, and immunohistochemical score, in renal cell carcinomas (RCCs) and explore their correlation with various clinicopathological aspects. Methodology We retrospectively obtained data and specimens from 87 patients diagnosed with RCC after partial or radical nephrectomy, and the CB1R and CB2R expression was assessed immunohistochemically on paraffin-embedded tissues. The results were statistically analyzed uni- and multi-factorial along with clinicopathological parameters. Results CB1R was not expressed at all, and CB2R was highly expressed in 78 (89.7%) patients with RCC. In unifactorial analysis, no statistical significance was found in any of the analyzed parameters. However, in the multifactorial analysis, we found that patients with a papillary histologic type (< 0.0005) were associated with a lower likelihood of expression of the CB2R in the membranous compared with those with clear-cell and were also associated with a higher likelihood of moderate or strong expression of CB2R immunohistochemical score compared with those with clear-cell (= 0.03). Patients with stage T2 (= 0.010) had more enhanced expression (grade 3 CB2R intensity) compared with those with stage T1. Males (beta coefficient ± standard error [SE] 13.70 ± 7.04; = 0.056) and patients with chromophobe histologic type (beta coefficient ± SE 23.45 ± 9.86; = 0.020) were associated with a higher percentage of CB2R expression. Conclusions Our data suggest that although the CB1R was not expressed in RCCs, CB2R was expressed in almost every patient and enhanced expression was noted in correlation with specific clinicopathological aspects of the patients. Thus, following well-designed studies, especially CB2R could be used as a prognostic marker or even as a potential therapeutic target in RCC.
背景与目的 我们研究的目的是评估1型大麻素受体（CB1R）和2型大麻素受体（CB2R）在肾细胞癌（RCC）中的表达情况，包括阳性率、强度、百分比、分布部位及免疫组化评分，并探讨它们与各种临床病理特征的相关性。方法 我们回顾性收集了87例接受部分或根治性肾切除术后诊断为RCC患者的数据和标本，采用免疫组化方法检测石蜡包埋组织中CB1R和CB2R的表达。将结果与临床病理参数进行单因素和多因素统计分析。结果 在RCC患者中，CB1R完全不表达，而CB2R在78例（89.7%）患者中高表达。单因素分析中，各分析参数均未发现统计学意义。然而，在多因素分析中，我们发现与透明细胞型患者相比，乳头状组织学类型的患者（<0.0005）CB2R膜表达的可能性较低，且与透明细胞型患者相比，其CB2R免疫组化评分中等或强表达的可能性较高（=0.03）。与T1期患者相比，T2期患者（=0.010）的CB2R表达增强（3级强度）。男性（β系数±标准误[SE] 13.70±7.04；=0.056）和嫌色细胞组织学类型的患者（β系数±SE 23.45±9.86；=0.020）CB2R表达百分比更高。结论 我们的数据表明，虽然CB1R在RCC中不表达，但CB2R在几乎所有患者中均有表达，且其表达增强与患者的特定临床病理特征相关。因此，经过精心设计的研究后，尤其是CB2R可作为RCC的预后标志物甚至潜在治疗靶点。
